In an interview during the Acute Leukemia Forum 2021, James Foran, MD, of Mayo Clinic, Jacksonville, discusses for which patients he might replace 7+3 with venetoclax-based therapies. Older patients with AML are often undertreated as a result of the barriers involved with intensive chemotherapy. Dr Foran notes that longer follow-up and prospective data are needed in order to offer the combination therapy of azacitidine/venetoclax to more patients.